Piper Sandler Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR)

Research analysts at Piper Sandler started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $35.00 price target on the biotechnology company’s stock. Piper Sandler’s price target would suggest a potential upside of 73.78% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $20.14 on Monday. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $23.40. The company has a market capitalization of $644.06 million, a PE ratio of -23.15 and a beta of 4.01. The company has a fifty day moving average of $9.70 and a 200-day moving average of $6.71.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. On average, equities analysts forecast that Capricor Therapeutics will post -1.13 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.00% of the stock is currently owned by company insiders.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Capricor Therapeutics in the second quarter worth approximately $426,000. Rhumbline Advisers bought a new position in shares of Capricor Therapeutics in the second quarter valued at approximately $147,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics during the first quarter valued at approximately $40,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.